title: [Basic studies on combination effects of arbekacin and beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus].
abstract: Combination effects were studied with arbekacin (ABK) and beta-lactam antibiotics including imipenem/cilastatin (IPM/CS), flomoxef (FMOX), and cefotiam (CTM) for bactericidal activities, post-antibiotic effects (PAE's) and bactericidal activities of beta-lactam antibiotics after removal of ABK using methicillin-resistant Staphylococcus aureus (MRSA) strain 1936. The following results were obtained. 1. When ABK was administered in combination with IPM/CS, FMOX or CTM against MRSA strain 1936, low FIC index was not obtained. 2. Higher bactericidal activity was observed when ABK was given before beta-lactam than when beta-lactam was given before ABK. 3. Combination of ABK and each of beta-lactam antibiotic led a longer PAE than ABK alone. 4. When each beta-lactam antibiotic was administered after a treatment and removal of ABK, greater bactericidal activity and growth inhibition were observed than when administered each beta-lactam alone. These findings basically demonstrated that ABK was effectively bactericidal against MRSA when administered in combination with beta-lactam antibiotic such as IPM/CS, FMOX or CTM, even when the FIC index did not indicate a favorable effect.
authors.affiliation: Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Sobu
authors.forename: Y
authors.initials: Y
authors.lastname: Takase
authors.forename: T
authors.initials: T
authors.lastname: Kawabata
authors.forename: M
authors.initials: M
authors.lastname: Kanno
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
mesh_terms: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015310:Cefotiam / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D015377:Cilastatin / Q000494:pharmacology; D003982:Dibekacin / Q000031:analogs & derivatives / Q000494:pharmacology; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D015378:Imipenem / Q000494:pharmacology; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D015377:Cilastatin; D003982:Dibekacin; D015378:Imipenem; D015310:Cefotiam; C031986:arbekacin; C045693:flomoxef